Aging Liver Cells Regain Their Filtering Role as Amyloid Beta and LDL Fall
The liver may be doing more work in age-related disease than most Alzheimer’s researchers have assumed. In a rat study from the Keck School of Medicine of USC, an experimental drug called cinaciguat restored structure and function in aging liver sinusoidal endothelial cells and cut circulating amyloid beta by about half after two weeks of treatment. LDL, the cholesterol fraction most closely tied to arterial plaque formation, also fell back to youthful levels. Those two results place a common metabolic organ squarely inside the biology of neurodegeneration and atherosclerosis.
The study’s focus was a specialized cell type often overlooked in routine discussions of liver disease: liver sinusoidal endothelial cells, or LSECs. These cells line tiny vascular channels in the liver and contain microscopic openings that help larger blood-borne molecules pass toward hepatocytes, the liver cells responsible for much of the body’s filtering and clearance work. With age, those openings shrink or disappear. Clearance slows, circulating waste accumulates, and substances with disease relevance — including amyloid beta — remain in the bloodstream longer than they should.
A single organ can influence two major age-related diseases through the chemistry of blood clearance.
Cinaciguat Reopened Microscopic Pores and Restored Clearance
Older rats received cinaciguat for two weeks, while other aged animals remained untreated and a younger group served as a comparator. After treatment, the aged LSECs regained their pore-like structure and their ability to support clearance from the bloodstream. Amyloid beta concentrations dropped by approximately 50%, reaching levels comparable to those seen in young animals. Untreated older rats showed no similar recovery.
The biological logic is straightforward even if the implication is striking. Amyloid beta is central to Alzheimer’s disease research because it can accumulate in the brain and contribute to plaque formation. The liver does not replace the brain as the organ of concern in Alzheimer’s disease, but it appears to influence how much amyloid beta is available in circulation in the first place. A stronger peripheral clearance system could reduce the burden that eventually reaches the central nervous system, although that connection remains unproven in humans.
The drug worked by activating soluble guanylate cyclase inside LSECs. That intracellular signal then restored the endothelial cells’ ability to function as aging had eroded it. In practical terms, cinaciguat did not merely change a biomarker; it reopened part of the liver’s filtration architecture.
LDL Fell Too, Exposing a Second Route Through Hepatocytes
The LDL result was the surprise. LDL particles are small enough that they do not depend on the microscopic openings in LSECs, so the investigators did not expect the drug to lower LDL at all. Instead, LDL levels in treated older rats also returned to youthful values.
One sentence captures the relevance: the liver’s recovery extended beyond a single sieve-like structure.
That unexpected fall in LDL pointed to a second layer of regulation, one involving communication between LSECs and hepatocytes. The researchers identified a previously unknown signaling sequence in which cinaciguat prompted LSECs to release HB-EGF, a growth factor that then altered hepatocyte surfaces. Those changes made hepatocytes more effective at capturing both LDL and amyloid beta from the blood. Aging had impaired this signal; cinaciguat restored it.
This matters because hepatocyte function has long been viewed as central to lipid handling, but the surrounding endothelial niche appears to influence whether those cells are working at full capacity. In that sense, the study reframes liver aging as a two-cell problem rather than a single-cell defect. The liver’s ability to clear blood-borne substances depends not only on the presence of hepatocytes, but also on the endothelial messages that tell hepatocytes how to behave.
Alzheimer’s and Atherosclerosis May Share a Peripheral Target
The appeal of the finding is obvious. Alzheimer’s disease has proved exceptionally difficult to treat through direct brain-targeting strategies, in part because the blood-brain barrier blocks many therapies from reaching their target. Systemic treatment directed at the liver sidesteps that obstacle. If a therapy can lower circulating amyloid beta before it ever reaches the brain, it opens a very different conceptual path for prevention.
The same logic extends to cardiovascular disease. LDL remains a primary driver of atherosclerosis, the process in which fatty deposits accumulate within arteries and restrict blood flow. By restoring youthful LDL handling in the liver, cinaciguat affected a pathway with clear relevance to plaque formation. The work suggests that a therapy designed for liver rejuvenation could, in principle, influence both cognitive and cardiovascular outcomes through shared metabolic biology.
Still, the experimental distance between rat physiology and human disease remains wide. The study did not show that amyloid plaques in the brain were reduced, and it did not show that Alzheimer’s disease was prevented. It did show that a drug can reverse age-related abnormalities in liver sinusoidal endothelial cells and normalize circulating amyloid beta and LDL in an animal model.
What the Study Demonstrates — and What It Does Not
Laurie DeLeve, MD, PhD, described the work as a reason for further translational research, especially because epidemiologic data already link age and liver damage to Alzheimer’s disease and atherosclerosis. Sam de Leve, the first author, pointed to the practical advantage of aiming drugs at the liver rather than trying to force them through the blood-brain barrier. That line of reasoning is persuasive, but it is still hypothesis-generating.
The report’s strongest claim is also its narrowest: this is the first study to show that a drug can fully restore the structure and function of aging LSECs while bringing age-related elevations in circulating amyloid beta and LDL back to youthful levels. It is an elegant mechanistic result, not yet a clinical one. The next questions are more demanding — whether the same effect appears in other models, whether it persists, and whether lowering blood amyloid beta can translate into meaningful protection against human Alzheimer’s disease.
The path from a rejuvenated rat liver to a preventable human dementia remains open, but not yet traveled.